Organon CEO Steps Down Amid Sales Malpractice Probe
Organon CEO Kevin Ali has resigned from his position following a board investigation that found evidence of sales malpractice.
The probe, conducted by the board's audit committee, revealed "inaccurate or incomplete" sales statements and "improper" wholesaler sales practices.
- The company encouraged US-based wholesalers to buy more of the contraceptive implant, Nexplanon, than needed.
The investigation found evidence of malpractice, resulting in Ali's resignation and a firing.
Author's summary: Organon CEO resigns amid sales probe.